TriSalus Life Sciences Inc (TLSI)
TriSalus Life Sciences Inc. is a healthcare company focused on developing and commercializing drug delivery technology and immuno-oncology therapies for patients with hard-to-treat liver and pancreatic cancers in the United States. The company’s platform includes Pressure-Enabled Drug Delivery (PEDD) systems, including the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for liver cancer and metastases. TriSalus is also advancing the Pancreatic Retrograde Venous Infusion device, which is in a Phase 1 clinical trial for locally advanced pancreatic cancer, as well as nelitolimod, an investigational immunotherapeutic being studied in Phase 1 trials across several cancer indications, including uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. Founded in 2009 and headquartered in Westminster, Colorado, the company serves clinicians and related healthcare decision-makers.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TLSI
|
$4.81
|
13.3% Upside
|
Fair
|
$9
|
111.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-4.6x
|
20.6x
|
5.9x
|
264.7 M
|
241.4 M
|
11.5%
|
80.3%
|
-3.5
|
—
|
35.6%
|
